PMID- 18636227
OWN - NLM
STAT- MEDLINE
DCOM- 20090107
LR  - 20211020
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 26
IP  - 2
DP  - 2008 Oct
TI  - Primary percutaneous coronary intervention for ST-elevation myocardial infarction 
      using an intravenous and subcutaneous enoxaparin low molecular weight heparin 
      regimen.
PG  - 85-90
LID - 10.1007/s11239-008-0258-2 [doi]
AB  - BACKGROUND: Enoxaparin use in PCI has been investigated, however its role in 
      primary PCI is less known. OBJECTIVE: To evaluate the role of combination IV + SC 
      enoxaparin in primary PCI in STEMI. METHODS: 83 consecutive patients with STEMI 
      who underwent primary PCI between January 1, 2005 and January 15, 2008 were 
      included. Anticoagulation was based on our institution's STEMI protocol; either 
      IV + SC enoxaparin, or IV unfractionated heparin (UFH). Clinical endpoints 
      included MACE, bleeding and net adverse cardiac events (NACE). RESULTS: 45 
      patients received UFH and 37 received IV + SC enoxaparin. There was no difference 
      in the rate of mortality, MACE, or NACE. There was a trend toward more TIMI major 
      and GUSTO moderate and severe bleeding in the UFH group. CONCLUSIONS: Application 
      of IV + SC enoxaparin strategy for primary PCI in STEMI appears both safe and 
      efficacious. A prospective randomized trial will be necessary to evaluate the 
      safety and efficacy more thoroughly.
FAU - Khoobiar, Sargis
AU  - Khoobiar S
AD  - Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ, 07112, 
      USA.
FAU - Mejevoi, Nicolai
AU  - Mejevoi N
FAU - Kaid, Khalil
AU  - Kaid K
FAU - Boiangiu, Catalin
AU  - Boiangiu C
FAU - Setty, Sampoornima
AU  - Setty S
FAU - Tanwir, Anjum
AU  - Tanwir A
FAU - Khalid, Khaula
AU  - Khalid K
FAU - Cohen, Marc
AU  - Cohen M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20080718
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Enoxaparin)
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/*adverse effects
MH  - Cardiovascular Diseases/etiology/mortality/*prevention & control
MH  - Enoxaparin/*administration & dosage/adverse effects
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Hemorrhage/chemically induced
MH  - Heparin/*administration & dosage/adverse effects
MH  - Humans
MH  - Injections, Intravenous
MH  - Injections, Subcutaneous
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/mortality/*therapy
MH  - Pilot Projects
MH  - Retrospective Studies
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2008/07/19 09:00
MHDA- 2009/01/08 09:00
CRDT- 2008/07/19 09:00
PHST- 2008/05/21 00:00 [received]
PHST- 2008/07/07 00:00 [accepted]
PHST- 2008/07/19 09:00 [pubmed]
PHST- 2009/01/08 09:00 [medline]
PHST- 2008/07/19 09:00 [entrez]
AID - 10.1007/s11239-008-0258-2 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2008 Oct;26(2):85-90. doi: 10.1007/s11239-008-0258-2. Epub 
      2008 Jul 18.